Comment on ‘Why do Australian dermatologists screen for Strongyloides stercoralis before dupilumab?’

Clicks: 11
ID: 331809
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #397 of 411 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 411 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In a retrospective cohort of 100 patients commencing dupilumab for atopic dermatitis, Strongyloides serology was positive or equivocal in 6%, with immunocompromised status strongly associated with seroreactivity. Although no hyperinfection or disseminated strongyloidiasis occurred over 319.6 patient-years, our findings support continued routine pretreatment screening and prophylaxis while prospective multicentre evidence and formal guidelines remain lacking.
Reference Key
openalex_W7220896873 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Timothy Chen, Heather Varcoe, Geoffrey Lee
Are you one of these authors? Claim your profile
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag442
URL
https://doi.org/10.1093/bjd/ljag442
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.